Cited by 72Cancer Genomics and DiagnosticsCancer-related Molecular PathwaysCancer Cells and Metastasis

Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers

Open access
Muzumdar, Mandar Deepak, Dorans, Kimberly Judith, Chung, Katherine Minjee, Robbins, Rebecca, Tammela, Tuomas, Gocheva, Vasilena, Li, Carman Man-Chung, Jacks, Tyler·2016·Nature Communications

Abstract

Although it has become increasingly clear that cancers display extensive cellular heterogeneity, the spatial growth dynamics of genetically distinct clones within developing solid tumours remain poorly understood. Here we leverage mosaic analysis with double markers (MADM) to trace subclonal populations retaining or lacking p53 within oncogenic Kras-initiated lung and pancreatic tumours. In both models, p53 constrains progression to advanced adenocarcinomas. Comparison of lineage-related p53 knockout and wild-type clones reveals a minor role of p53 in suppressing cell expansion in lung adenomas. In contrast, p53 loss promotes both the initiation and expansion of low-grade pancreatic intraepithelial neoplasia (PanINs), likely through differential expression of the p53 regulator p19ARF. Strikingly, lineage-related cells are often dispersed in lung adenomas and PanINs, contrasting with more contiguous growth of advanced subclones. Together, these results support cancer type-specific suppressive roles of p53 in early tumour progression and offer insights into clonal growth patterns during tumour development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms12685

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TP53 mutational inactivation is a clonal and predominantly early event in established NSCLC that precedes genome doubling and subsequent branched evolution.

    “This notion is further supported by identification of TP53 mutational inactivation as a clonal and predominantly early event in established NSCLC that precedes genome doubling and subsequent branched evolution74, 103.”
  • Mutational inactivation of RB1 is a clonal and early genetic event in 9.5%-12.5% of EGFR-mutant LUAD.

    “Mutational inactivation of RB1 is a clonal and early genetic event in 9.5%−12.5% of EGFR-mutant LUAD72, 73, 103, 117.”
  • TP53 co-mutations impact the natural history of EGFR-mutant NSCLC at least partially by allowing tolerance of a greater degree of genomic instability that results in larger numbers of co-occurring truncal drivers and late sub-clonal diversification with focal emergence of high amplitude amplifications and deletions in mediators of therapeutic resistance.

    “Therefore, TP53 co-mutations impact the natural history of EGFR-mutant NSCLC at least partially by allowing tolerance of a greater degree of genomic instability that results in both larger numbers of co-occurring truncal drivers as well as late sub-clonal diversification with focal emergence of high amplitude amplifications and deletions in mediators of therapeutic resistance103.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Young N. P. & Jacks T. Tissue-specific p19ARF regulation dictates response to oncogenic K-ras. Proc. Natl Acad. Sci. USA 107, 10184– 10189 (2010). 20479239 PMC2890471
  2. Waclaw B.. Spatial model predicts dispersal and cell turnover cause reduced intra-tumor heterogeneity. Nature 525, 261– 264 (2015). 26308893 PMC4782800

Cited by

Sorted by citations

Authors
Muzumdar, M. D., Dorans, K. J., Chung, K. M., Robbins, R., Tammela, T., Gocheva, V., Li, C. M.-C., & Jacks, T.
Affiliations
  • Harvard University (US)
  • Koch Institute for Integrative Cancer Research At MIT (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Jacks, Tyler
Venue
Nature Communications
Published
2016-09-02
Volume
7
Issue
1
Pages
12685-12685
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2516559527
Cited by
72
References
44
Citations by year
2026: 6 · 2025: 7 · 2024: 4 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 7 · 2019: 7 · 2018: 9 · 2017: 8
FWCI
3.33
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
  • Nature
Funders
  • Howard Hughes Medical Institute
  • Harvard University (KL2 TR001100)
  • Harvard Catalyst (KL2 TR001100, TR001100)
  • National Institutes of Health (KL2TR001100)
  • Ludwig Center at Harvard
  • National Cancer Institute (CA14051, P30CA014051, P30-CA-14051)
  • National Center for Research Resources
  • National Center for Advancing Translational Sciences (TR001100)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
p53, loss of heterozygosity, clonal dynamics, lung adenocarcinoma, pancreatic intraepithelial neoplasia, subclonal evolution, p19ARF, tumor progression, tumor heterogeneity, lineage tracing
MeSH terms
Adenocarcinoma, Animals, Lung Neoplasms, Mice, Transgenic, Pancreatic Neoplasms, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Disease Progression, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Cell Proliferation, Mice, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review